Analysis
Healthleap has raised $38 million combined across a $8 million seed round, co-led by Sequoia Capital and First Round Capital, and a $30 million Series A led by Hummingbird Ventures, the company said this week.
Healthleap's AI platform analyzes patient records — pulling from both provider notes and structured data — to flag hospitalized patients who may have undiagnosed conditions like malnutrition, delirium, aspiration pneumonia or pressure ulcers that busy clinical staff might otherwise miss, according to TechCrunch.
Founded in South Africa in 2022 by siblings Jemima and Josiah Meyer, Healthleap started with a $1.1 million pre-seed round and is now deployed in more than 50 hospitals, including Penn Medicine, Cedars-Sinai and Intermountain Health. The company says it has grown revenue 10x year over year and prices on a mix of outcome-based and bed-count models rather than a flat per-seat SaaS fee — a structure that ties Healthleap's growth directly to how much hospitals actually rely on its flags, rather than how many logins they've purchased.
“A disclosed accuracy or false-positive rate for its flags — not the 10x growth number — is the metric hospital systems will actually use to decide whether to renew.”
Clinical-decision-support AI has drawn plenty of funded entrants in the past two years, though Healthleap's specific angle — catching conditions doctors miss in patients already admitted, rather than diagnosing from scratch — is a narrower and arguably lower-risk wedge than many of its AI-diagnosis peers, since it's flagging for human review rather than making a call itself.
The 10x revenue growth figure is impressive on its face, but worth reading against the company's small starting base and its reference-customer list rather than as a standalone claim: hospital systems adopt clinical software slowly and renew it even more slowly, so the real test of Healthleap's traction is retention at Penn Medicine and Cedars-Sinai past the first contract cycle, not the growth rate off a low starting point.
A disclosed accuracy or false-positive rate for its flags — not the 10x growth number — is the metric hospital systems will actually use to decide whether to renew.
